Clinical Trials on Polycytemia Vera

Total 467 results

Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Ronald Hoffman
Novartis

Unknown

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-Essential Thrombocythemia Related Myelofibrosis

United States
M.D. Anderson Cancer Center

Recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
John Mascarenhas

Terminated

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related Myelofibrosis

United States
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Novartis Pharmaceuticals

Completed

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Polycythemia Vera (PV)

United States
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
PharmaEssentia Japan K.K.

Recruiting

A Study to Evaluate P1101 in Japanese PV Patients

Polycythemia Vera (PV)

Japan
PharmaEssentia Japan K.K.

Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Polycythemia Vera (PV)

Japan
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phlebotomy Dependent Polycythemia Vera

United States, Canada, Hungary, United Kingdom, Australia, Poland
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
Novartis Pharmaceuticals

Terminated

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocytopenia

United States
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Primary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Primary Myelofibrosis | Splenomegaly | Hepatomegaly | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy, United Kingdom, France
Sierra Oncology LLC - a GSK company

Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Canada, Germany, Australia
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
RWTH Aachen University
Novartis Pharmaceuticals

Active, not recruiting

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)

Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Germany
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Real-world Ruxolitinib Experience in PV (REVIEW)

Polycythemia Vera
Perseus Proteomics Inc.

Recruiting

Safety Evaluation Study for Patients With Polycythemia Vera

Polycythemia Vera

Japan
Protagonist Therapeutics, Inc.

Completed

PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)

Polycythemia Vera

Korea, Republic of, Malaysia
Protagonist Therapeutics, Inc.

Active, not recruiting

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

Polycythemia Vera

United States, India
Italfarmaco

Completed

Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV)

Polycythemia Vera

Italy
Novartis Pharmaceuticals

Completed

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Polycythemia Vera

Germany, Belgium, France, Austria, Canada, Thailand, Norway, Bulgaria, Portugal, Chile, Mexico, Sweden
Weill Medical College of Cornell University
Bristol-Myers Squibb

Terminated

Dasatinib in Polycythemia Vera

Polycythemia Vera

United States
Exelixis

Terminated

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Polycythemia Vera

United States
Weill Medical College of Cornell University

Completed

Treatment of Polycythemia Vera With Gleevec

Polycythemia Vera

United States
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Real World Evidence of Fedratinib Effectiveness in MF (REALFed)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Italy
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Korea, Republic of, Malaysia, Italy, Germany, United Kingdom, Thailand, Poland, Turkey
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Novartis Pharmaceuticals

Completed

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis (JAKoMo)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Germany
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
Incyte Corporation

Completed

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Italfarmaco

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera (GIV-IN PV)

Polycythemia Vera

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

Polycythemia Vera

China
Novartis Pharmaceuticals

Recruiting

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors (HU-F-AIM)

Polycythemia Vera

Germany
Silence Therapeutics plc

Recruiting

Study to Assess SLN124 in Patients With Polycythemia Vera (SLN)

Polycythemia Vera

United States, Australia, Malaysia, Bulgaria, Poland
PharmaEssentia

Recruiting

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Polycythemia Vera

United States, Canada
Protagonist Therapeutics, Inc.

Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

Polycythemia Vera

United States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
University of Birmingham
Novartis; National Cancer Institute, France; MPN Voice

Recruiting

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE)

Polycythemia Vera

United Kingdom
Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Polycythemia Vera

United States, Australia, United Kingdom
PharmaEssentia

Active, not recruiting

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Polycythemia Vera

China
Novartis Pharmaceuticals

Available

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Polycythemia Vera
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (for the U.S.)

Completed

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

Polycythemia Vera

Spain, Austria, Bulgaria, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine, Czechia
Kartos Therapeutics, Inc.

Unknown

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Polycythemia Vera

United States, Poland, Spain, Germany, Hungary, France

Clinical Trials on Polycytemia Vera

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations